Screener
Syndax Pharmaceuticals SNDX Total Current Assets
Total Current Assets at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AssetsCurrent.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Other receivables, net | 267 | 6,404 |
| Collaboration receivable, net | 20,507 | 23,745 |
| Prepaid expenses and other current assets | 16,100 | 13,496 |
| Total current assets | 471,177 | 528,081 |
| Property and equipment, net | 177 | 181 |
| Right-of-use asset, net | 1,212 | 1,342 |
| Restricted cash | 102 | 102 |
| Total assets | $472,668 | $529,706 |
Item 1: Financial Statements
FAQ
- What is Syndax Pharmaceuticals's total current assets?
- Syndax Pharmaceuticals (SNDX) reported total current assets of $471.18M in Q1 2026.
- How has Syndax Pharmaceuticals's total current assets changed year-over-year?
- Syndax Pharmaceuticals's total current assets decreased by 14.1% year-over-year, from $548.75M to $471.18M.
- What is the long-term trend for Syndax Pharmaceuticals's total current assets?
- Over 5 years (2020 to 2025), Syndax Pharmaceuticals's total current assets has grown at a 12.1% compound annual growth rate (CAGR), from $298.86M to $528.08M.
- What does total current assets mean?
- The sum of all assets expected to be converted to cash or consumed within one year — cash, receivables, inventory, and prepaid expenses.
Ask your AI about Syndax Pharmaceuticals's total current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude